paperKB
coga / coga-kb
Help
Sign in

Chunk #55 — SUD Prevalence and qEEG Changes — qEEG and ERP Abnormalities in Addiction: Psychopharmacological Effects or Trait Markers? — Heritability and Neurotransmitter Considerations in Substance Use Disorders

Source
EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research.
Embedded
yes

Text

Blum and colleagues (1990, 1993, 1996) described this syndrome and identified the D2 dopamine receptor gene as a possible candidate for susceptibility to alcoholism in severe alcoholics (Blum et al. 1993) and proposed this gene’s association with dopamine production and distribution may produce a sevenfold increase in the likelihood of developing alcohol use problems (Uhl et al. 1993). This DRD2 dopamine receptor gene and polymorphisms within its genetic coding specific to addiction remain unclear due to its involvement in other disorders; including, obesity (Blum et al. 2006), Tourette’s syndrome (Comings et al. 1991) pathological aggression and violence, PTSD (Comings et al. 1996) and schizoid—avoidant disorder (Chen et al. 2005). SUD were classified as a subtype of RDS and treatment regimens for these disorders have been classified as inadequate (Blum et al. 2007) and research continues in developing possible genetic interventions that may produce dopamine and other neurotransmitter regulation in substance-induced rapid dopamine increase in limbic regions (Blum et al. 2007).